<DOC>
	<DOCNO>NCT00491725</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial evaluate efficacy safety repaglinide metformin combination therapy Chinese subject type 2 diabetes inadequately control OAD ( oral anti-diabetic drug ) .</brief_summary>
	<brief_title>Efficacy Safety Repaglinide Metformin Combination Therapy Type 2 Diabetes Failing Oral Anti-diabetic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes least 12 week HbA1c : 8.010.0 % Current treatment OAD monotheray OAD combination therapy Body mass index ( BMI ) : 21.035.0 kg/m2 Known suspect allergy trial product ( ) relate product Recurrent major hypoglycaemia judge Investigator Uncontrolled hypertension Any significant condition concomitant disease endocrine , cardiac , neurological , malignant pancreatic disease judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>